Bank of New York Mellon Corp Invests $60.62 Million in Insulet Corporation $PODD

Key Points

• Bank of New York Mellon acquired 398,130 Insulet shares during the second quarter, worth approximately $60.62 million and representing about 0.57% of the company.
• Insulet reported a strong second quarter, with adjusted EPS of $1.66 and revenue of $801.7 million, beating estimates; revenue rose 23.5% year over year.
• Despite the earnings beat, shares face concerns over revised 2026 guidance, Omnipod recalls and related securities litigation allegations. Analysts have lowered price targets, and the stock carries a consensus “Hold” rating with a $195.40 target.

Bank of New York Mellon Corp acquired a new position in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 398,130 shares of the medical instruments supplier's stock, valued at approximately $60,615,000. Bank of New York Mellon Corp owned about 0.57% of Insulet at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PODD. Glenmede Investment Management LP grew its stake in shares of Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier's stock valued at $708,000 after acquiring an additional 35 shares during the period. Curi Capital LLC raised its stake in Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock worth $1,365,000 after acquiring an additional 36 shares during the period. Great Lakes Advisors LLC raised its stake in Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier's stock worth $791,000 after acquiring an additional 40 shares during the period. Camarda Financial Advisors LLC lifted its holdings in Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier's stock valued at $2,304,000 after purchasing an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares during the period.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the business's stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.36% of the company's stock.

Insulet Price Performance

NASDAQ:PODD opened at $143.38 on Thursday. The business's 50-day moving average is $154.52 and its 200 day moving average is $182.09. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a market capitalization of $9.94 billion, a P/E ratio of 26.80, a P/E/G ratio of 1.13 and a beta of 1.10. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. During the same quarter last year, the business posted $1.17 EPS. The firm's revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PODD shares. Weiss Ratings cut shares of Insulet from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, June 24th. Piper Sandler dropped their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. BTIG Research lowered Insulet from a "buy" rating to a "neutral" rating in a research note on Thursday, August 6th. Barclays decreased their price target on Insulet from $286.00 to $198.00 and set an "underweight" rating on the stock in a report on Thursday, May 7th. Finally, Robert W. Baird set a $175.00 price objective on Insulet in a research report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Insulet presently has an average rating of "Hold" and a consensus target price of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source